AptarGroup Reports $982.9M in Q1 Sales, Net Income Down 8%

By Chris Stiles • Friday, May 01 04:43 • Permanent Link

AptarGroup reported first-quarter 2026 sales of $982.9 million, up 11% from $887.3 million a year earlier, while core sales were flat.

Reported net income fell 8% to $73 million, and reported earnings per share slipped to $1.12 from $1.17. Adjusted earnings per share declined to $1.19 from $1.30, an 8% drop at constant currency. Adjusted EBITDA margin narrowed to 19.2% from 20.7%.

The company said it returned $131 million to shareholders in the quarter through dividends and share repurchases, including the repurchase of 707,000 shares for $100 million.

By segment, pharma reported sales rose 7%, beauty sales climbed 19%, and closures sales increased 5%. Core sales were down 1% in pharma, up 3% in beauty, and flat in closures.

Within pharma, prescription dispensing systems sales fell 10%, consumer healthcare sales rose 4%, injectables sales jumped 20%, and active material science solutions declined 1%.

Margin pressure was visible across all three segments. Pharma adjusted EBITDA margin fell 150 basis points to 33.3%, beauty margin declined 100 basis points to 11.1%, and closures margin dropped 270 basis points to 13.1%.

The company’s effective tax rate for the quarter was 22.4%, down from 25.8% a year earlier, while the adjusted effective tax rate was 22.6% versus 25.8%.

For the second quarter, Aptar expects adjusted earnings per share of $1.32 to $1.40. The board also approved a quarterly dividend of $0.48 per share. The market has reacted to these announcements by moving the company's shares -0.69% to a price of $124.08. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.